arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Werewolf Therapeutics, Inc.

HOWL

$1.02 ▼ -0.07 (-6.42%) at close

7 Visible periods

22 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Werewolf Therapeutics, Inc. faces fundamental challenges with weakness in Debt to Equity. The fundamentals warrant careful consideration of downside risks.

Market Cap $46.9M

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -84.3% ↘

FCF / Share $-1.31 →

Trailing P/E —

Price / Book 2.0x

FCF Yield —

Debt / Equity 1.29

info Valuation on last close. End-of-day price, Nov 5, 2026.

7-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Net Income Profit after all expenses

$-60.82M

↑ +13.7% —

FCF / Share Free cash flow per share

$-1.31

↓ -0.6% —

Long-Term Debt Long-term obligations

$32.09M

— 0.0% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Debt to EquityDebt to Equity is concerning (bottom quartile)
Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓

Financial Health ↑

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
EPS Growth YoY (%)	19.0% Good ↓ Good Declining Year-over-year change in earnings per share Optimal: > 10%	-55.2% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	43.5% Excellent ↓ Excellent Declining Year-over-year change in earnings per share Optimal: > 10%	83.0% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	61.0% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—
Net Income Growth YoY (%)	13.7% Fair ↑ Fair Improving Year-over-year change in net income	-88.7% Weak ↓ Weak Declining Year-over-year change in net income	30.6% Excellent ↑ Excellent Improving Year-over-year change in net income	-7.7% Weak Weak Year-over-year change in net income	-232.3% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	-0.6% Weak ↓ Weak Declining Year-over-year change in free cash flow	-39.1% Weak ↓ Weak Declining Year-over-year change in free cash flow	38.9% Excellent ↓ Excellent Declining Year-over-year change in free cash flow	34.8% Excellent Excellent Year-over-year change in free cash flow	87.7% Excellent Excellent Year-over-year change in free cash flow	—	—

💰 Are margins durable? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
FCF / Net Income (x)	0.99x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.80x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.89x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.82x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.87x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	1.28x Good Good Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Return on Invested Capital (%)	-84.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-55.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-21.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-36.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-25.9% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	34.1% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-87.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-58.0% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-23.2% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-35.0% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-27.9% Weak Weak Operating profit relative to total assets Optimal: > 10%	-23.2% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-245.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1735%)	-96.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-741%)	-33.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-324%)	-44.0% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-393%)	-32.7% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-318%)	29.0% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+93%)	—

⚖️ Is the balance sheet risky? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Debt to Equity (x)	1.29x Caution ↑ Caution Improving Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Above avg (+116%)	0.44x Good Good Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-27%)	0.36x Good Good Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-40%)	—	—	—	—
Interest Coverage (x)	-11.50x Weak ↑ Weak Improving Operating income divided by interest expense Optimal: > 5x	-22.23x Weak Weak Operating income divided by interest expense Optimal: > 5x	-12.90x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	—	—
Net Debt (USD)	$-24.96M	$-78.91M	$-94.34M	$-129.31M	$-157.53M	$-92.57M	—
Debt / EBITDA (x)	-0.54x Excellent ↑ Excellent Improving Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-0.45x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	-1.03x Excellent Excellent Debt relative to earnings before interest, taxes, depreciation Optimal: < 2x	—	—	—	—

📊 What does each share earn? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Basic EPS, GAAP (USD)	$-1.32	$-1.63	$-1.05	$-1.86	$-10.94	$-28.08	—
Free Cash Flow per Share (USD)	$-1.31	$-1.30	$-0.94	$-1.53	$-2.35	$-19.09	—
Book Value per Share (USD)	$0.51	$1.64	$2.85	$3.89	$5.59	$-43.80	—
Tangible Book Value per Share (USD)	$0.51	$1.64	$2.85	$3.89	$5.59	$-43.80	—
Basic Weighted Avg Shares (shares)	46.02M	43.33M	35.65M	28.86M	18.45M	1.00M	—

🏦 How resilient is the balance sheet? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Working Capital (USD)	$22.44M	$97.89M	$118.99M	$116.21M	$149.19M	$87.63M	—
LT Debt (USD)	$32.09M	$32.09M	$40.00M	—	—	—	—
Total Equity (USD)	$24.80M	$73.39M	$111.37M	$122.34M	$152.79M	$-51.86M	$-24.30M

📋 What is driving earnings? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Depreciation Expense (USD)	$1.63M	$1.81M	$1.76M	$1.10M	$216.00K	$150.00K	—
Net Income, GAAP (USD)	$-60.82M	$-70.52M	$-37.37M	$-53.81M	$-49.98M	$-15.04M	—
Operating Cash Flow (USD)	$-60.29M	$-56.19M	$-32.61M	$-40.60M	$-42.88M	$-18.62M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 7 years · 27 quarters

Werewolf Therapeutics, Inc.

Analytical Summary

7-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare HOWL with peers